Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial

European Urology

Volumn 62, Issue 5, 2012, Pages 757-764

  Muller, Roberto L ^a,b   Gerber, Leah ^a,b   Moreira, Daniel M ^c   Andriole, Gerald ^d   Castro Santamaria, Ramiro ^e   Freedland, Stephen J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c The Arthur Smith Institute for Urology   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

5 Reductase inhibitors therapeutic use; Gonadal steroid hormones; Middle aged; Prostate specific antigen blood; Prostatic neoplasms diagnosis

Indexed keywords

ANDROGEN; ANDROSTANOLONE; DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL;

5-ALPHA REDUCTASE INHIBITORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AZASTEROIDS; BIOPSY; DIHYDROTESTOSTERONE; DOUBLE-BLIND METHOD; HUMANS; KALLIKREINS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASMS, HORMONE-DEPENDENT; ODDS RATIO; PLACEBOS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84867052045     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.05.025     Document Type: Article

References (27)

1. C. Huggins, C.V. Hodges Studies on prostatic cancer I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, 1941 J Urol 168 2002 9 12
2. N.E. Eaton, G.K. Reeves, and P.N. Appleby Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies Br J Cancer 80 1999 930 934
3. E. Barrett-Connor, C. Garland, and J.B. McPhillips A prospective, population-based study of androstenedione, estrogens, and prostatic cancer Cancer Res 50 1990 169 173
4. J.K. Parsons, H.B. Carter, and E.A. Platz Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy Cancer Epidemiol Biomarkers Prev 14 2005 2257 2260
5. A.W. Roddam, N.E. Allen, and P. Appleby Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 2008 170 183
6. A. Morgentaler, C.O. Bruning III, and W.C. DeWolf Occult prostate cancer in men with low serum testosterone levels JAMA 276 1996 1904 1906
7. A. Morgentaler, and E.L. Rhoden Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less Urology 68 2006 1263 1267
8. B.R. Lane, A.J. Stephenson, and C. Magi-Galluzzi Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy Urology 72 2008 1240 1245
9. A. Salonia, A. Gallina, and A. Briganti Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy Cancer 117 2011 3953 3962
10. G. Isom-Batz, F.J. Bianco Jr., and M.W. Kattan Testosterone as a predictor of pathological stage in clinically localized prostate cancer J Urol 173 2005 1935 1937
11. C. Kratzik, I. Womastek, and C. Bieglmayer Lower serum total testosterone is associated with lymph node metastases in a radical prostatectomy cohort study Anticancer Res 31 2011 3615 3618
12. S.S. Chen, K.K. Chen, and A.T. Lin The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis BJU Int 89 2002 710 713
13. A. Morgentaler Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship Eur Urol 52 2007 623 625
14. J.M. Monda, R.P. Myers, and D.G. Bostwick The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration Urology 46 1995 62 64
15. H. Isbarn, J.H. Pinthus, and L.S. Marks Testosterone and prostate cancer: revisiting old paradigms Eur Urol 56 2009 48 56
16. J.P. Weber, J.E. Oesterling, and C.A. Peters The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia J Urol 141 1989 987 992
17. A.S. Wright, R.C. Douglas, and L.N. Thomas Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase Endocrinology 140 1999 4509 4515
18. A. Morgentaler, and A.M. Traish Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth Eur Urol 55 2009 310 321
19. L.S. Marks, N.A. Mazer, and E. Mostaghel Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial JAMA 296 2006 2351 2361
20. G. Andriole, D. Bostwick, and O. Brawley Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial J Urol 172 2004 1314 1317
21. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
22. F.Z. Stanczyk, J.S. Lee, and R.J. Santen Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 16 2007 1713 1719
23. C. Wu, D.M. Moreira, and L. Gerber Diabetes and prostate cancer risk in the REDUCE trial Prostate Cancer Prostatic Dis 14 2011 326 331
24. J. Cuzick A Wilcoxon-type test for trend Stat Med 4 1985 87 90
25. S. Bhasin, G.R. Cunningham, and F.J. Hayes Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 95 2010 2536 2559
26. H.L. Parnes, I.M. Thompson, and L.G. Ford Prevention of hormone-related cancers: prostate cancer J Clin Oncol 23 2005 368 377
27. A.W. Hsing, L.W. Chu, and F.Z. Stanczyk Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prev 17 2008 2525 2530